Valuation: Almirall SA

Market Cap 2.38B 2.75B 2.22B 2.04B 3.86B 262B 3.9B 26.1B 10.24B 131B 10.33B 10.1B 433B P/E 2026 *
27.8x
P/E 2027 * 20x
Enterprise Value 2.27B 2.62B 2.12B 1.95B 3.68B 249B 3.72B 24.89B 9.77B 125B 9.85B 9.64B 413B EV / Sales 2026 *
1.85x
EV / Sales 2027 * 1.57x
Free-Float
35.93%
Yield 2026 *
1.85%
Yield 2027 * 1.92%
Manager TitleAgeSince
Chief Executive Officer - 02/11/2022
Director of Finance/CFO 53 31/08/2025
Chief Tech/Sci/R&D Officer - 07/07/2021
Director TitleAgeSince
Director/Board Member - 01/01/2014
Director/Board Member - 01/01/2016
Chairman - 06/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
+3.85%-4.01%+51.64%+155.79% 995B
+1.35%-2.56%+51.53%+49.46% 614B
+0.51%-6.60%+23.86%+63.59% 431B
+1.96%+0.83%+42.80%+37.70% 353B
-0.11%-4.07%+30.37%+38.52% 293B
+2.52%-8.36%+7.27%+10.56% 245B
+3.37%+4.45%+34.93%+60.08% 210B
-4.32%-12.94%-3.79%-46.07% 210B
-3.07%-0.66%+17.25%+63.46% 168B
Average +0.72%-5.02%+28.43%+48.12% 390.92B
Weighted average by Cap. +1.57%-5.89%+36.53%+72.07%

Financials

2026 *2027 *
Net sales 1.23B 1.42B 1.15B 1.05B 1.99B 135B 2.01B 13.47B 5.29B 67.54B 5.33B 5.21B 224B 1.36B 1.57B 1.26B 1.16B 2.2B 149B 2.22B 14.86B 5.83B 74.51B 5.88B 5.75B 247B
Net income 84.14M 97.15M 78.44M 72.14M 136M 9.24B 138M 922M 362M 4.62B 365M 357M 15.31B 116M 134M 108M 99.78M 188M 12.78B 190M 1.27B 500M 6.39B 505M 494M 21.17B
Net Debt -111M -128M -103M -94.76M -179M -12.13B -181M -1.21B -475M -6.07B -479M -469M -20.11B -255M -295M -238M -219M -413M -28B -417M -2.79B -1.1B -14.01B -1.11B -1.08B -46.41B
Logo Almirall SA
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A